Changeflow GovPing Healthcare & Life Sciences Phase 3 Ovarian Cancer Trial, Decitabine Primin...
Routine Notice Added Final

Phase 3 Ovarian Cancer Trial, Decitabine Priming Added

Email

Summary

ClinicalTrials.gov record for NCT02159820: a Phase 3 interventional study evaluating decitabine priming in ovarian cancer treatment. The trial is registered as an active study with an overall status of 'Recruiting'. No regulatory compliance deadlines, enforcement actions, or substantive rule changes are associated with this database entry.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 3 Oncology Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.

What changed

This entry documents the registration of a Phase 3 clinical trial (NCT02159820) investigating decitabine priming in ovarian cancer on ClinicalTrials.gov, the NIH-maintained clinical study database. The listing provides basic trial metadata including study title, condition (ovarian cancer), intervention (decitabine), and recruitment status. No regulatory obligations, compliance deadlines, or enforcement actions are created by this database entry.

Affected parties including clinical investigators, pharmaceutical sponsors, and institutional review boards should note this trial represents active Phase 3 oncology research. This registration does not constitute FDA approval or endorsement of the investigated therapy.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 3 Oncology Trials

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Clinical investigators Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Clinical trial registration Oncology research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 3 Oncology Trials publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!